Establishment Labs (NASDAQ:ESTA – Get Free Report) had its target price raised by research analysts at Citigroup from $45.00 to $50.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price indicates a potential upside of 30.68% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Mizuho upped their target price on shares of Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, June 6th. JPMorgan Chase & Co. decreased their target price on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, Stephens restated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average target price of $57.60.
Read Our Latest Stock Analysis on ESTA
Establishment Labs Price Performance
Establishment Labs (NASDAQ:ESTA – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The company had revenue of $44.12 million for the quarter, compared to the consensus estimate of $43.10 million. During the same period last year, the company earned ($0.65) EPS. The firm’s revenue for the quarter was down 9.2% on a year-over-year basis. On average, analysts forecast that Establishment Labs will post -2.2 EPS for the current fiscal year.
Insider Activity
In related news, CEO Quiros Juan Jose Chacon sold 3,866 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $45.01, for a total value of $174,008.66. Following the sale, the chief executive officer now directly owns 215,030 shares of the company’s stock, valued at approximately $9,678,500.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.44% of the company’s stock.
Hedge Funds Weigh In On Establishment Labs
A number of institutional investors have recently modified their holdings of ESTA. Capital Research Global Investors purchased a new position in shares of Establishment Labs during the first quarter worth approximately $45,888,000. William Blair Investment Management LLC bought a new position in shares of Establishment Labs during the first quarter valued at approximately $21,415,000. First Turn Management LLC bought a new position in shares of Establishment Labs during the second quarter valued at approximately $16,812,000. Sofinnova Investments Inc. boosted its stake in shares of Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock valued at $19,505,000 after purchasing an additional 288,082 shares in the last quarter. Finally, Divisadero Street Capital Management LP bought a new position in shares of Establishment Labs during the second quarter valued at approximately $5,829,000. 72.91% of the stock is owned by hedge funds and other institutional investors.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Read More
- Five stocks we like better than Establishment Labs
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Consumer Discretionary Stocks Explained
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.